A Study of Anlotinib in Subjects With Advanced Malignancy

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04216082
• Collaborator: (none)
• Enrollment: 93
• Location: 1
• Arm: 1
• Actual Duration (Months): 24
• Patients Per Site Per Month: 3.9

Study Details

Study Description

Brief Summary

Anlotinib is a tyrosine kinase inhibitors (TKI) with high effective in inhibiting angiogenesis and tumor cell proliferation by targeting VEGFR, PDGFR, FGFR and c-Kit. Previous phase I trial has shown the potency of anlotinib in treating patients with various cancer types who failed in standard treatment or lack proper treatment regimen. Here, a single center, single-arm, phase II study was conducted to further validate the efficacy and safety of anlotinib in these patients.

Condition or Disease	Intervention/Treatment	Phase
Advanced Malignancy	Drug: Anlotinib	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 93 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Single Center, Single-arm, Phase II Study of Anlotinib in Subjects With Advanced Malignancy
• Actual Study Start Date: Aug 1, 2013
• Actual Primary Completion Date: Aug 31, 2014
• Actual Study Completion Date: Aug 1, 2015

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Anlotinib Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Drug: Anlotinib; Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Outcome Measures

Primary Outcome Measures

1. Overall response rate (ORR) [up to 96 weeks]

   Percentage of subjects achieving complete response (CR) and partial response (PR).

Secondary Outcome Measures

1. Progression-free survival (PFS) [up to 96 weeks]

   PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

2. Disease control rate（DCR） [up to 96 weeks]

   Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).

3. Duration of Response (DOR) [up to 96 weeks]

   DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• 1. 18~70 years old; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Life expectancy ≥ 3 months.

1. Histopathologically confirmed advanced malignancy, including gynecological-related tumors, breast cancer, digestive tract tumors, melanoma, and gastrointestinal stromal tumors.

2. Has no effective treatment choice, or failure/recurrence after conventional treatment.

3. If has received chemotherapy, the treatment has been discontinued for at least 30 days.

4. The main organs function are normally. 6) Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.

5. Understood and signed an informed consent form.

Exclusion Criteria:

• 1）Has other malignant tumors. 2) Has participated in other anticancer drug clinical trials within 4 weeks. 3) Has multiple factors affecting oral medication. 4) Has brain metastasis, spinal cord compression, cancerous meningitis. 5) Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.

1. Has any serious and / or uncontrolled disease. 7) Long-term unhealed wounds or fractures. 8) Has artery/venous thrombosis prior to the first dose within 6 months. 9) Has bleeding tendency or treated with anticoagulants or vitamin K antagonists.

2. Has drug abuse history that unable to abstain from or mental disorders. 11)Has history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.

3. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing	Beijing	China	100021

Sponsors and Collaborators

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• ClinicalTrials.gov Identifier: NCT04216082
• Other Study ID Numbers: ALTN-00-II
• First Posted: Jan 2, 2020
• Last Update Posted: Jan 2, 2020
• Last Verified: Dec 1, 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Neoplasms

Study Results

No Results Posted as of Jan 2, 2020